Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma

Jing Qin, Qian Zhao, Hongfang Jin, Xiao Xu, Zhixia Yue, Maoquan Qin, Hongjun Fan, Tong Yu, He Le-jian, Hong Qin, Xiaoli MaResearch 2020 · DOI

Abstract

Neuroblastoma (NB) is a highly heterogeneous extracranial solid tumor in children. While its clinical presentation varies, periorbital metastasis—often manifesting as "raccoon eyes"—is a hallmark of advanced, high-risk disease. This study retrospectively analyzed 40 patients to summarize the clinical characteristics and short-term prognosis of this specific subgroup. The findings reveal that periorbital involvement is associated with universal systemic spread, high rates of MYCN amplification, and a dismal 5-year overall survival rate of 16%.

Introduction

Neuroblastoma is the most common extracranial solid tumor in the pediatric population. Its clinical course can range from spontaneous regression to rapid, fatal progression. Patients presenting with periorbital metastasis represent a particularly aggressive subset. These symptoms often lead parents to seek initial consultation with ophthalmologists, potentially delaying the diagnosis of the underlying systemic malignancy. This paper details the clinical profile, genetic markers, and outcomes for these high-risk patients to improve diagnostic awareness and prognostic accuracy.

Methods

The study cohort consisted of 40 pediatric patients (25 boys, 15 girls) treated at the Hematology-Oncology Center of Beijing Children’s Hospital between March 2007 and March 2018.

Staging and Treatment

All patients were staged according to the International Neuroblastoma Staging System (INSS) and classified as high-risk. They followed the BCH-HR-NB-2007 protocol, an intensive 18-month multi-modal regimen including:

  1. Induction: Multi-agent chemotherapy.
  2. Local Control: Surgical resection and external beam radiation.
  3. Consolidation: Myeloablative chemotherapy followed by autologous stem cell rescue.
  4. Maintenance: Isotretinoin therapy.

Data Analysis

Researchers utilized Kaplan-Meier survival curves and log-rank tests to evaluate Event-Free Survival (EFS) and Overall Survival (OS). Genetic testing for MYCN amplification and chromosomal G-banding was performed for risk stratification.

Clinical Presentation and the "Ophthalmology Trap"

A significant finding of this study is the diagnostic delay caused by the localized nature of initial symptoms. Approximately 65% of the children were first seen in ophthalmology clinics for periorbital masses or bruising. In one documented case, a child received topical eye drops for two weeks before a CT scan identified the metastatic mass.

Table 1: Clinical features of the 40 patients, highlighting the prevalence of periorbital symptoms and primary tumor locations.

As shown in Table 1, periorbital mass and bruising were the dominant symptoms (92.5%). The primary tumor was most frequently located in the retroperitoneum or adrenal area (92.5%). Critically, periorbital metastasis was never an isolated finding; 100% of patients had concurrent bone and bone marrow metastasis at the time of diagnosis.

Biological Markers and Survival Outcomes

The biological profile of these tumors further underscores their aggression. The rate of MYCN amplification was 44.7%, nearly double the rate typically seen in the general neuroblastoma population. Elevated levels of lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) were also prevalent.

Table 3: Biological features and survival analysis of the patient cohort.

Despite intensive therapy, the prognosis remains poor. The 5-year Event-Free Survival (EFS) was 6%, and the 5-year Overall Survival (OS) was 16%. As detailed in Table 3, high levels of LDH (>1500 U/L) and NSE (>370 ng/ml) were common, and 82.5% of patients experienced tumor progression or recurrence, with a median time to progression of only 9 months.

Discussion and Conclusion

Periorbital metastasis in neuroblastoma is a clinical "red flag" for systemic, high-risk disease. The high frequency of multi-organ involvement—including the lymph nodes (32.5%), dura mater (27.5%), and brain parenchyma (7.5%)—indicates that these patients require aggressive, systemic intervention from the outset.

Improving outcomes will require:

  1. Increased Awareness: Educating primary care providers and ophthalmologists to recognize "raccoon eyes" as a potential oncological emergency.
  2. Targeted Research: Investigating the biological drivers that cause certain neuroblastomas to migrate to periorbital tissues.
  3. Novel Therapies: Integrating immunotherapy and targeted agents into existing protocols to combat the high rates of recurrence and progression seen in this cohort.

Summary updated

Abstract

Abstract Background This study was performed to summarize the clinical characteristics of patients with periorbital metastasis of neuroblastoma (NB) and analyze the short-term prognosis. Methods This study included 40 patients with periorbital metastasis of NB from March 2007 to March 2018. The patients’ clinical characteristics and short-term prognosis were retrospectively analyzed. Results The 40 patients comprised 25 boys and 15 girls with a median age at onset of 31 months (range, 8–132 months). The patients’ symptoms included a periorbital mass and eye bruising (n = 37, 92.5%), limb pain (n = 14, 35.0%), a head and neck mass (n = 8, 20.0%), fever (n = 8, 20.0%), an abdominal mass (n = 4, 10.0%), weakness (n = 3, 7.5%), abdominal pain (n = 2, 5.0%), anemia (n = 2, 5.0%), and others (n = 3, 7.5%). All 40 patients had stage IV, high-risk NB. Various auxiliary structures of the eye were involved: ocular muscles (n = 11, 27.5%), lacrimal glands (n = 4, 10.0%), optic nerve (n = 2, 5.0%), and eyelid (n = 1 2.5%). Fifteen patients (37.5%) had tumor invasion in a periorbital sinus cavity. All patients had bone marrow and bone metastasis. Of 38 patients with a known MYCN gene status, 17 patients (44.7%) had MYCN amplification. The median follow-up duration was 19 months (range, 4–144 months). The 5-year event-free survival rate was 6%, and the 5-year overall survival rate was 16%. Conclusions Patients with periorbital metastasis of NB often have multi-organ metastases, extremely high rates of MYCN amplification and bone marrow metastasis, and a poor short-term prognosis.
BibTeX
@inproceedings{qin2020clinical,
  author = {Jing Qin and Qian Zhao and Hongfang Jin and Xiao Xu and Zhixia Yue and Maoquan Qin and Hongjun Fan and Tong Yu and HE Le-jian and Hong Qin and Xiaoli Ma},
  title = {{Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.2.23016/v1},
}
Figure